Amneal Pharmaceuticals spent the second quarter of 2026 transforming itself from a generics-and-specialty hybrid into something with a third leg: a U.S.-based biosimilars franchise. On April 21, the company signed a definitive agreement to acquire 100% of Kashiv BioSciences, a related-party biopharmaceutical firm that is one of the few U.S. manufacturers of approved biosimilars, for $375 million in cash plus 28,942,108 shares of Class A stock and up to $350 million in regulatory milestone payments. The deal is shareholder-approved and expected to close in the third quarter of 2026, which means every line of the second-quarter print - Q2 net revenue of $796 million, GAAP diluted EPS of $0.18, and a 7% lift in full-year 2026 revenue guidance to $3.10–$3.20 billion - sits underneath a question that will resolve in roughly ninety days.
The Q2 print itself was strong on the surface but a touch less clean under the hood. Net revenue grew 9.9% year-over-year to $796 million, gross margin expanded by roughly 250 basis points to 42.0%, and GAAP net income nearly doubled to $69.6 million from $35.6 million. Operating income rose 16.5% to $129.8 million, and adjusted diluted EPS climbed 20% to $0.30. But operating cash flow swung to a $48.0 million use in the first half from a $91.2 million source a year earlier, and free cash flow before the Kashiv cash payment was negative because the company paid $35.9 million on the Nationwide Opioids Settlement, $38.8 million on the tax receivable agreement, and $75.0 million up front for a mirabegron product rights intangible. None of those are recurring in the same shape next year, but together they explain why a profitable quarter on a GAAP basis produced a cash burn.
What the market is pricing, in our view, is the multiple-expansion logic of the Kashiv deal: biosimilars are a higher-multiple, higher-durability vertical than retail generics, and adding a domestic biosimilar manufacturing footprint to Amneal's existing specialty and generics platform compresses the equity's "generic-only" valuation discount. With shares closing at $18.42 on August 15 and roughly 319.4 million Class A shares outstanding, market cap is approximately $5.9 billion, against $2.6 billion of net debt and a $2.6 billion term loan plus senior notes stack. The deal-funded capital structure is the load-bearing risk: it relies on closing the Kashiv transaction on schedule, integrating a separate biosimilar pipeline, and absorbing roughly $20 million of second-half 2026 lost pre-tax profit from a July water-damage event at an India manufacturing facility.
The single falsifiable clock is the third-quarter 2026 close. The Q2 print and the second-half 2026 guide assume Kashiv closes; if it slips, or if integration costs run materially above the $30 million already excluded from operating cash flow guidance, the equity re-rating thesis pauses. The next data point is the Q3 10-Q, which will print the first quarter of consolidated Kashiv results if closing holds.